Latest news

Thumbnail image for Teva’s subcutaneous asthma drug fails in PhIII

Teva’s subcutaneous asthma drug fails in PhIII

Teva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets.

23rd January 2018

Thumbnail image for Rexgenero wins £1.4m grant from Innovate UK

Rexgenero wins £1.4m grant from Innovate UK

London, UK-based Rexgenero has secured with partners £1.4 million in funding for a £1.8 million project from the UK’s innovation agency Innovate UK, for an industrial research project on the commercial manufacture of its product REX-001.

23rd January 2018

Thumbnail image for NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition

NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition

Cost regulators for NHS-funded therapies in England and Wales have issued updated guidelines for the treatment of wet AMD, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis, but the GMC says doctors should not fear prescribing Roche's Avastin off-label if they believe it is clinically appropriate and in the patient's best interest.

23rd January 2018

Thumbnail image for Biosimilar Avastin wins EU approval

Biosimilar Avastin wins EU approval

European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region.

22nd January 2018

Thumbnail image for Biogen ‘optimistic’ for NHS access to Spinraza

Biogen ‘optimistic’ for NHS access to Spinraza

Biogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder will get rapid and broad access to Spinraza via the National Health Service in England and Wales.

22nd January 2018

Thumbnail image for Sanofi shells out $11.6bn on Bioverativ

Sanofi shells out $11.6bn on Bioverativ

Sanofi is fortifying its presence in the field of blood disorders through the purchase of Bioverativ in a deal valued at some $11.6 billion.

22nd January 2018

Thumbnail image for Report calls for urgent action on R&D model

Report calls for urgent action on R&D model

“Urgent action” is required to boost the productivity of the UK’s R&D model, which is grappling with “unprecedented pressure”, claims a new report by Medicines Discovery Catapult and the BioIndustry Association.

18th January 2018

Thumbnail image for GPs dealing with ‘unsafe’ work load

GPs dealing with ‘unsafe’ work load

GPs in the UK are dealing with an average of 41.5 patient contacts every day, which is 60 percent more than what is deemed safe by peers in Europe, an investigation by Pulse has revealed.

18th January 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download